⚠ Evidence warning: Clinical trials or other evidence do not support the claims that goldenseal whole-root extract is significantly more antibacterial in vitro than purified berberine alone and that another berberine source is equally effective for general antimicrobial, blood-sugar or anti-diarrheal use. This page keeps it as a report of what people, websites or other media say.

Goldenseal — Benefits Deep Dive

Benefits — scientific infographic poster

Goldenseal (Hydrastis canadensis), the bright-yellow-rooted woodland perennial Native Americans called "yellow root," is one of the most therapeutically potent and most ecologically endangered herbs in the Western herbal pharmacopeia. Its bioactivity comes from a trio of isoquinoline alkaloids — berberine (broad-spectrum antimicrobial and DNA-gyrase inhibitor), hydrastine (mucous-membrane astringent and vasoconstrictor), and canadine (tetrahydroberberine, a fully reduced relative of berberine). A century of overharvesting from old-growth Appalachian hardwood forests has placed Hydrastis canadensis on CITES Appendix II and the United Plant Savers "At-Risk" list — the conservation concern centres on wild-harvested (wild-crafted) root, while cultivated and woods-grown root does not draw on wild populations. For everyday berberine needs, the more abundant Oregon grape (Mahonia aquifolium) or barberry (Berberis vulgaris) deliver the same primary alkaloid without the conservation cost. The four deep-dive pages below cover goldenseal's most clinically supported uses (antimicrobial, digestive/gut, eye health) alongside the conservation status of the wild plant.

Deep-Dive Articles

🦠

Antimicrobial Activity

The berberine + hydrastine + canadine alkaloid trio and its broad-spectrum activity against Gram-positive (methicillin-resistant Staphylococcus aureus (MRSA), Strep pyogenes, C. difficile) and Gram-negative (E. coli, H. pylori, Chlamydia) bacteria. DNA-gyrase inhibition, FtsZ blockade, the Stermitz efflux-pump-inhibitor discovery, traditional Native American wound and infection use, and the in vitro methicillin-resistant Staphylococcus aureus biofilm data that drives modern antibiotic-adjuvant research.

Read the deep dive →
🍽️

Digestive & Gut Health

Bitter-principle stimulation of saliva, gastric acid, and bile flow; in-gut antimicrobial action against bacterial diarrhea (E. coli, V. cholerae, Shigella); a 2014 Johns Hopkins retrospective chart review in which herbal formulas (the abstract does not name goldenseal) cleared small intestinal bacterial overgrowth (SIBO) on breath testing in 46% of patients versus 34% on rifaximin, a difference that was not statistically significant; berberine inhibition of C. difficile toxin A/B; pilot inflammatory bowel disease (IBD) adjunct studies; and the practical comparison to cheaper berberine sources (barberry, Oregon grape, purified berberine HCl) for gut applications.

Read the deep dive →
👁️

Eye Health

Goldenseal's traditional "eye-cleaning" name origin from Cherokee and Iroquois conjunctivitis eyewashes. Berberine's in vitro activity against common conjunctivitis organisms (Staph aureus, Strep pneumoniae, Haemophilus influenzae). A 1982 Indian Journal of Ophthalmology clinical trial of berberine in trachoma. The safety concerns — contamination of unfiltered home decoctions, use in babies, and the shift practitioners describe toward commercial sterile eye drops.

Read the deep dive →
🌍

Sustainability & Cautions

The conservation case: Hydrastis canadensis CITES Appendix II listing (1997), United Plant Savers "At-Risk" placement, state-level endangered listings in 12+ states, and the century of overharvest from Appalachian hardwood forests that produced this crisis. Cultivated vs woods-grown vs wild-crafted distinctions, the Forest Grown Verified (FGV) certification scheme, and the cheaper, more abundant berberine sources — Oregon grape (Mahonia aquifolium), barberry (Berberis vulgaris), or purified berberine HCl — that supply the same main alkaloid without goldenseal's unique alkaloid profile.

Read the deep dive →

Back to Table of Contents

Table of Contents

  1. Deep-Dive Articles
  2. Why Goldenseal Produces Effects
  3. Sustainability: Why Wild Goldenseal Is at Risk
  4. Research Papers: Antimicrobial
  5. Research Papers: Digestive & Gut
  6. Research Papers: Eye Health
  7. Research Papers: Sustainability & Safety
  8. Research Papers: Cross-Cutting (Mechanism, Synergy, Alternatives)
  9. External Authoritative Resources
  10. Connections
  11. Featured Videos

Sustainability: Why Wild Goldenseal Is at Risk

Goldenseal is one of the most overharvested medicinal plants in North America.

Hydrastis canadensis has been listed on CITES Appendix II since 1997 (Convention on International Trade in Endangered Species) and sits on the United Plant Savers "At-Risk" list, the most urgent botanical conservation category. Wild populations have collapsed by an estimated 50%+ over the past century due to a combination of overharvesting for the medicinal trade and the loss of mature deciduous-forest habitat that goldenseal requires.

How goldenseal reaches the market:

  • Goldenseal is sold as cultivated root, as woods-grown root (covered by the Forest Grown Verified certification scheme), and as wild-harvested root. Cultivated and woods-grown root does not draw on wild populations, and some suppliers document the chain of custody.
  • Wild-harvested (wild-crafted) root is the part of the trade that draws down wild populations; it is the reason United Plant Savers, a conservation nonprofit, lists goldenseal as At-Risk.
  • Cheaper and more abundant berberine sources exist: Oregon grape (Mahonia aquifolium), barberry (Berberis vulgaris), or purified berberine HCl supplements. All contain berberine, the primary antimicrobial alkaloid, and none draws on wild goldenseal.
  • The effects credited to goldenseal's full alkaloid profile rather than berberine alone centre on the mucous-membrane astringency attributed to hydrastine; in laboratory tests, the compounds that boost berberine against bacteria came from goldenseal leaves, not from the root alkaloids (see the next section). For general antimicrobial, blood-sugar, or anti-diarrheal use, an alternative is equally effective.

See the Sustainability & Cautions deep dive for the full conservation story and a comparison of goldenseal with its alternatives.

Back to Table of Contents

Why Goldenseal Produces Effects

Goldenseal's clinical actions are not the product of a single dominant compound; they are the product of a coordinated three-alkaloid system in which the major alkaloid (berberine) does most of the antimicrobial heavy lifting and two minor alkaloids (hydrastine and canadine) each contribute distinct, complementary effects that are difficult to replicate with a single purified compound.

  1. Berberine — broad-spectrum antimicrobial (2.5-6% of dried root by weight). Berberine is a quaternary ammonium isoquinoline alkaloid present at the highest concentration of the three. It is the source of goldenseal's most-studied actions: DNA intercalation and gyrase inhibition, FtsZ (bacterial cell-division protein) blockade, AMP-activated protein kinase (AMPK) activation (the basis for berberine's blood-glucose-lowering effects), NF-kB suppression (anti-inflammatory), and broad direct antibacterial activity against both Gram-positive and Gram-negative pathogens. Crucially, berberine is also found at therapeutic concentrations in Oregon grape and barberry, which is why those plants are listed as the sustainable substitutes for most goldenseal indications.
  2. Hydrastine — mucous-membrane astringent and vasoconstrictor (1.5-4% by weight). Hydrastine is a phthalideisoquinoline alkaloid unique to Hydrastis canadensis — it is the alkaloid that distinguishes goldenseal from other berberine-containing plants. Its astringent and mild vasoconstrictive properties give goldenseal its traditional reputation for "tightening up" inflamed mucous membranes, which is why Eclectic-era physicians prized it for catarrhal conditions (nasal congestion, postnasal drip, mucousy diarrhea, bronchial congestion). Laboratory work found that hydrastine, like berberine and canadine, is not what gives goldenseal extracts their ability to block the NorA multidrug-resistance efflux pump of Staphylococcus aureus (Ettefagh 2011, PubMed PMID: 21157683).
  3. Canadine (tetrahydroberberine) — a minor alkaloid (0.5-1% by weight). Canadine is structurally a fully reduced berberine analogue. It has often been described as goldenseal's built-in blocker of the bacterial NorA efflux pump, but laboratory tests point elsewhere. Ettefagh and colleagues (2011) found that extracts of goldenseal's above-ground parts boosted berberine against Staphylococcus aureus more strongly (fractional inhibitory concentration 0.375) than root extract did (0.750); only the above-ground extract blocked the pump, the root extract showed no pump-blocking activity, and berberine, hydrastine and canadine were not responsible for it (PubMed PMID: 21157683). In plain words: the root is rich in berberine, the alkaloid that kills the bacteria, while the “helper” compounds that block the NorA pump are three flavonoids (sideroxylin, 8-desmethyl-sideroxylin and 6-desmethyl-sideroxylin) found mostly in the leaves; on their own they do not kill S. aureus. The researchers suggest that an extract combining roots and leaves might work best against S. aureus (Junio 2011, PubMed PMID: 21661731). All of this is test-tube work, not studies in people. It is a well-documented observation that goldenseal whole-root extract is significantly more antibacterial in vitro than purified berberine alone.

The practical point is that for effects that come from berberine (anti-diarrheal action, blood-glucose lowering, basic antimicrobial activity, anti-inflammatory effects), cheaper and more sustainable berberine sources contain the same alkaloid. The effects credited to goldenseal's wider profile — mucous-membrane astringency from hydrastine, and the leaf-flavonoid synergy with berberine seen in laboratory tests — are narrower. Herbalists who weigh conservation describe reserving goldenseal for those uses rather than treating it as a generic "natural antibiotic".

A second therapeutic complication is that the same alkaloids that make goldenseal effective also make it among the most drug-interaction-prone herbs on the shelf: berberine is reported to inhibit several cytochrome P450 (CYP) liver enzymes (CYP2D6, CYP2C9 and CYP3A4), which control the clearance of a long list of prescription drugs, and the effect has been measured in people. In 12 healthy volunteers taking goldenseal for 28 days, the activity of CYP2D6 and CYP3A4/5 fell by about 40% (the same study also tested kava, black cohosh and valerian); the authors warn that serious adverse interactions may result when goldenseal is taken with drugs cleared by those enzymes (Gurley 2005, PubMed PMID: 15900287). In 16 healthy volunteers, a goldenseal product standardized to berberine raised the blood level (AUC) of midazolam, a drug cleared by CYP3A, by 43% and lowered the blood level of the diabetes drug metformin by 23%, with no effect on rosuvastatin or furosemide; the authors note that the metformin drop may have unfavorable effects on glucose control (Nguyen 2021, PubMed PMID: 33174626). For the drug pump P-glycoprotein the human data show little effect: in 20 volunteers, goldenseal (3,210 mg a day for 14 days) did not significantly change digoxin levels apart from a 14% rise in peak level, and the authors concluded that it is not a potent modulator of P-glycoprotein in the body (Gurley 2007, PubMed PMID: 17079360). The fourth deep-dive page explores the full safety profile including the strict pregnancy contraindication (uterine stimulation, bilirubin displacement from albumin, and a documented neonatal jaundice risk).

Back to Table of Contents

Research Papers: Antimicrobial

  1. Stermitz FR, Lorenz P, Tawara JN, Zenewicz LA, Lewis K (2000). Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5'-methoxyhydnocarpin, a multidrug pump inhibitor. Proceedings of the National Academy of Sciences of the USA 97(4):1433-1437. (5'-methoxyhydnocarpin was isolated from Berberis, not goldenseal.) — PubMed PMID: 10677479
  2. Scazzocchio F, Cometa MF, Tomassini L, Palmery M (2001). Antibacterial activity of Hydrastis canadensis extract and its major isolated alkaloids. Planta Medica 67(6):561-564. — PubMed PMID: 11509983
  3. Ettefagh KA, Burns JT, Junio HA, Kaatz GW, Cech NB (2011). Goldenseal (Hydrastis canadensis L.) extracts synergistically enhance the antibacterial activity of berberine via efflux pump inhibition. Planta Medica 77(8):835-840. — PubMed PMID: 21157683
  4. Cech NB, Junio HA, Ackermann LW, Kavanaugh JS, Horswill AR (2012). Quorum quenching and antimicrobial activity of goldenseal (Hydrastis canadensis) against methicillin-resistant Staphylococcus aureus (MRSA). Planta Medica 78(14):1556-1561. — PubMed PMID: 22814821
  5. Domadia PN, Bhunia A, Sivaraman J, Swarup S, Dasgupta D (2008). Berberine targets assembly of Escherichia coli cell division protein FtsZ. Biochemistry 47(10):3225-3234. — PubMed PMID: 18275156
  6. Berberine DNA-gyrase / topoisomerase II inhibition — PubMed: Berberine DNA gyrase
  7. Berberine activity against MRSA and biofilm formation — PubMed: Berberine MRSA biofilm
  8. Junio HA, Sy-Cordero AA, Ettefagh KA, Burns JT, Micko KT, Graf TN, Richter SJ, Cannon RE, Oberlies NH, Cech NB (2011). Synergy-directed fractionation of botanical medicines: a case study with goldenseal (Hydrastis canadensis). Journal of Natural Products 74(7):1621-1629. (NorA efflux pump inhibition by goldenseal leaf flavonoids.) — PubMed PMID: 21661731
  9. Berberine + beta-lactam antibiotic synergy against MRSA — PubMed: Berberine + beta-lactam
  10. Berberine antibacterial against Chlamydia trachomatis — PubMed: Berberine + Chlamydia

Back to Table of Contents

Research Papers: Digestive & Gut

  1. Rabbani GH, Butler T, Knight J, Sanyal SC, Alam K (1987). Randomized controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic Escherichia coli and Vibrio cholerae. Journal of Infectious Diseases 155(5):979-984. — PubMed PMID: 3549923
  2. Berberine inhibition of C. difficile toxin A and toxin B production — PubMed: Berberine + C. difficile toxin
  3. Chedid V, Dhalla S, Clarke JO, Roland BC, Dunbar KB, Koh J, Justino E, Tomakin E, Mullin GE (2014). Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Global Advances in Health and Medicine 3(3):16-24. (A retrospective review of 104 patients; goldenseal is not named in the abstract.) — PubMed PMID: 24891990
  4. Berberine inhibition of cholera toxin / heat-labile enterotoxin Cl- channels — PubMed: Berberine + cholera Cl- channels
  5. Berberine activity against Helicobacter pylori — PubMed: Berberine + H. pylori
  6. Bitter principles, vagal stimulation, and gastric acid / bile secretion — PubMed: Bitter principles + GI secretion
  7. Berberine pilot data in inflammatory bowel disease (IBD adjunct) — PubMed: Berberine + IBD
  8. Berberine and intestinal barrier / tight junction protein expression — PubMed: Berberine + tight junctions
  9. Berberine modulation of gut microbiota composition — PubMed: Berberine + gut microbiota
  10. Berberine for traveler's diarrhea prophylaxis — PubMed: Berberine + traveler's diarrhea

Back to Table of Contents

Research Papers: Eye Health

  1. Mohan M, Pant CR, Angra SK, Mahajan VM (1982). Berberine in trachoma. (A clinical trial). Indian Journal of Ophthalmology 30(2):69-75. — PubMed PMID: 6754599
  2. Berberine in vitro activity against conjunctivitis pathogens (S. aureus, S. pneumoniae, H. influenzae) — PubMed: Berberine + conjunctivitis pathogens
  3. Berberine activity against Chlamydia trachomatis ocular infection (trachoma) — PubMed: Berberine + trachoma
  4. Berberine suppression of conjunctival IL-1beta and TNF-alpha — PubMed: Berberine + conjunctival cytokines
  5. Goldenseal eyewash historical pharmacopeia documentation (Eclectic and USP) — PubMed: Goldenseal eyewash history
  6. Bacterial conjunctivitis pathogen distribution (modern epidemiology) — PubMed: Bacterial conjunctivitis epidemiology
  7. Berberine ocular pharmacokinetics and safety — PubMed: Berberine ocular pharmacokinetics
  8. Self-prepared herbal eyewash contamination / endophthalmitis case reports — PubMed: Eyewash contamination risks
  9. Neonatal jaundice and ophthalmic berberine exposure (kernicterus risk) — PubMed: Berberine + neonatal jaundice
  10. Berberine and corneal epithelial wound healing — PubMed: Berberine + corneal healing

Back to Table of Contents

Research Papers: Sustainability & Safety

  1. CITES Appendix II listing of Hydrastis canadensis (1997) — PubMed: CITES Hydrastis
  2. United Plant Savers At-Risk list methodology and goldenseal status — PubMed: United Plant Savers
  3. Goldenseal wild population decline and habitat loss in Appalachia — PubMed: Wild population decline
  4. Woods-grown / forest-grown verified goldenseal cultivation methods — PubMed: Woods-grown cultivation
  5. Berberine and CYP450 cytochrome P450 drug interactions — PubMed: Berberine + CYP450
  6. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A (2005). In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clinical Pharmacology and Therapeutics 77(5):415-426. — PubMed PMID: 15900287
  7. Nguyen JT, Tian DD, Tanna RS, Hadi DL, Bansal S, Calamia JC, Arian CM, Shireman LM, Molnár B, Horváth M, Kellogg JJ, Layton ME, White JR, Cech NB, Boyce RD, Unadkat JD, Thummel KE, Paine MF (2021). Assessing Transporter-Mediated Natural Product-Drug Interactions Via In vitro-In Vivo Extrapolation: Clinical Evaluation With a Probe Cocktail. Clinical Pharmacology and Therapeutics 109(5):1342-1352. — PubMed PMID: 33174626
  8. Goldenseal effects on P-glycoprotein drug transporter — PubMed: Goldenseal + P-glycoprotein
  9. Gurley BJ, Swain A, Barone GW, Williams DK, Breen P, Yates CR, Stuart LB, Hubbard MA, Tong Y, Cheboyina S (2007). Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metabolism and Disposition 35(2):240-245. — PubMed PMID: 17079360
  10. Berberine teratogenicity and uterine stimulation in animal studies — PubMed: Berberine + pregnancy
  11. Berberine displacement of bilirubin from albumin (neonatal jaundice mechanism) — PubMed: Berberine + bilirubin
  12. Hydrastine vasoconstriction and blood pressure effects — PubMed: Hydrastine + blood pressure

Back to Table of Contents

Research Papers: Cross-Cutting (Mechanism, Synergy, Alternatives)

  1. Mahonia aquifolium (Oregon grape) berberine content and antimicrobial profile — PubMed: Oregon grape berberine
  2. Berberis vulgaris (barberry) berberine pharmacology — PubMed: Barberry berberine
  3. Berberine HCl oral bioavailability and absorption — PubMed: Berberine HCl bioavailability
  4. Berberine activation of AMPK and metabolic effects — PubMed: Berberine + AMPK
  5. Berberine vs metformin in type 2 diabetes meta-analysis — PubMed: Berberine vs metformin
  6. Berberine NF-kB inhibition and anti-inflammatory effects — PubMed: Berberine + NF-kB
  7. Goldenseal + echinacea combination for upper respiratory infection — PubMed: Goldenseal + echinacea
  8. Comparative phytochemistry of berberine-containing plants — PubMed: Comparative berberine plants
  9. Coptis chinensis (Chinese goldthread) as sustainable berberine alternative — PubMed: Coptis chinensis

Back to Table of Contents

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents